Departament d'Infermeria, Facultat de Medicina, Universitat Autonoma de Barcelona, Avda. Can Domenech, Building M. Office M3/211, Bellaterra (Cerdanyola del Vallès), 08193, Barcelona, Spain.
Center for Health Sciences Research, Universidad María Auxiliadora, Av. Canto Bello 431, San Juan de Lurigancho, Lima, Lima, 15408, Peru.
AIDS Res Ther. 2019 Aug 28;16(1):22. doi: 10.1186/s12981-019-0238-y.
There are approximately 72,000 people living with HIV/AIDS (PLHIV) in Peru. Non-adherence to antiretroviral therapy (ART) is the most important factor for therapeutic failure and the development of resistance. Peru has achieved moderate progress in meeting the 90-90-90 targets, but only 60% of PLHIV receiving ART are virally suppressed. The purpose of this study was to understand ART adherence in the Peruvian context, including developing sociodemographic and clinical profiles, evaluating the clinical management strategies, and analyzing the relationships between the variables and adherence of PLHIV managed at a regional HIV clinic in Lambayeque Province (Northern Peru).
This was a cross-sectional study with 180 PLHIV adults, non-randomly but consecutively selected with self-reported ART compliance (78.2% of the eligible population). The PLHIV profile (PLHIV-Pro) and the Simplified Medication Adherence Questionnaire (SMAQ) were used to collect sociodemographic information, clinical variables, and data specific to ART adherence. Descriptive analysis of sociodemographic and clinical characteristics was performed. Bivariate analysis was performed with the Mann-Whitney test, Chi square test, and Yates correction.
The 180 PLHIV sample included 78.9% men, 49.4% heterosexual, 45% with a detectable HIV-1 viral load less than 40 copies/ml, 58.3% not consistently adherent, and only 26.1% receiving Tenofovir + Lamivudine + Efavirenz. Risk factors significant for non-adherence included concurrent tuberculosis, discomfort with the ART regime, and previous pauses in ART. Multivariate analysis of nested models indicated having children is a protector factor for adherence.
Self-reported adherence appeared to be low and the use of first-line therapy is not being prescribed homogeneously. Factors associated with nonadherence are both medical and behavioral, such as having tuberculosis, pausing ART, or experiencing discomfort with ART. The Peruvian government needs to update national technical standards, monitor medication availability, and provide education to health care professionals in alignment with evidence-based guidelines and international recommendations. Instruments to measure adherence need to be developed and evaluated for use in Latin America.
秘鲁约有 72000 名艾滋病毒感染者(PLHIV)。不遵守抗逆转录病毒治疗(ART)是治疗失败和产生耐药性的最重要因素。秘鲁在实现 90-90-90 目标方面取得了适度进展,但仅 60%接受 ART 的 PLHIV 病毒得到抑制。本研究旨在了解秘鲁的 ART 依从性,包括制定社会人口学和临床概况,评估临床管理策略,并分析在兰巴耶克省(秘鲁北部)的一个区域艾滋病毒诊所接受治疗的 PLHIV 的变量和依从性之间的关系。
这是一项横断面研究,纳入了 180 名成年 PLHIV,通过自我报告的 ART 依从性(合格人群的 78.2%)非随机但连续选择。PLHIV 概况(PLHIV-Pro)和简化用药依从性问卷(SMAQ)用于收集社会人口学信息、临床变量和特定于 ART 依从性的数据。对社会人口学和临床特征进行描述性分析。采用 Mann-Whitney 检验、卡方检验和 Yates 校正进行二变量分析。
180 名 PLHIV 样本包括 78.9%的男性、49.4%的异性恋者、45%的 HIV-1 病毒载量可检测但小于 40 拷贝/ml、58.3%的不持续依从、只有 26.1%接受替诺福韦+拉米夫定+依非韦伦。与不依从相关的危险因素包括并发结核病、对 ART 方案不适和 ART 中断。嵌套模型的多变量分析表明,有孩子是依从的保护因素。
自我报告的依从性似乎较低,一线治疗的使用并未统一规定。与不依从相关的因素既有医疗因素,也有行为因素,如患有结核病、暂停 ART 或对 ART 不适。秘鲁政府需要更新国家技术标准,监测药物供应,并根据循证指南和国际建议为卫生保健专业人员提供教育。需要开发和评估衡量依从性的工具,以在拉丁美洲使用。